Patents by Inventor Tzyy-Rong Jinn

Tzyy-Rong Jinn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7588885
    Abstract: The present invention relates to use of bicistronic DNA constructs for identifying compounds that inhibits IRES-dependent translation activity of an infectious enterovirus (EV) or encephalomyocarditis virus (EMCV) without affecting CAP-dependent translation activity of a host subject. The compounds thus identified are useful in preparation of a medicament for treating EV or EMCV infection.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: September 15, 2009
    Assignee: Chung Yuan Christian University
    Inventors: Tzong-Yuan Wu, Shin-Jhan Zeng, Ying-Ju Chen, Tsu-An Hsu, Shin-Ru Shih, Suey-Sheng Kao, Tzyy-Rong Jinn
  • Publication number: 20080241922
    Abstract: The present invention relates to use of bicistronic DNA constructs for identifying compounds that inhibits IRES-dependent translation activity of an infectious enterovirus (EV) or encephalomyocarditis virus (EMCV) without affecting CAP-dependent translation activity of a host subject. The compounds thus identified are useful in preparation of a medicament for treating EV or EMCV infection.
    Type: Application
    Filed: July 23, 2007
    Publication date: October 2, 2008
    Applicant: CHUNG YUAN CHRISTIAN UNIVERSITY
    Inventors: Tzong-Yuan Wu, Shin-Jhan Zeng, Ying-Ju Chen, Tsu-An Hsu, Shin-Ru Shih, Suey-Sheng Kao, Tzyy-Rong Jinn
  • Publication number: 20080242734
    Abstract: The present invention relates to use of bicistronic DNA constructs for identifying compounds that inhibits IRES-dependent translation activity of an infectious enterovirus (EV) or encephalomyocarditis virus (EMCV) without affecting CAP-dependent translation activity of a host subject. The compounds thus identified are useful in preparation of a medicament for treating EV or EMCV infection.
    Type: Application
    Filed: July 23, 2007
    Publication date: October 2, 2008
    Applicant: CHUNG YUAN CHRISTIAN UNIVERSITY
    Inventors: Tzong-Yuan Wu, Shin-Jhan Zeng, Ying-Ju Chen, Tsu-An Hsu, Shin-Ru Shih, Suey-Sheng Kao, Tzyy-Rong Jinn
  • Publication number: 20070293459
    Abstract: The present invention discloses an inhibitive effect of Na+—K+-ATPase caused by a compound selected from the group consisting of magnesium lithospermate B (MLB), isomer, prodrug, derivative, pharmaceutically acceptable salt, and a composition thereof. In this invention, the variations of Na+—K+-ATPase activity were monitored with increasing MLB concentrations, and the result shows the Na+—K+ ATPase activity is repressed by MLB. An outcome of the inhibitory effect, the function of cellular sodium/potassium exchanger is reduced and cellular calcium ion concentration is increased. The cerebral ischemia test exhibited MLB provides an effective repression of cell infarct. That is, the MLB is useful for inhibiting the function of cellular Na+—K+ pump, and further brings the utility for cardiac stimulation, diuretic enhancement, heart failure curing, anti-anoxia, neurocyte apoptosis protection, apoplexy prevention and treatment, and so on.
    Type: Application
    Filed: October 20, 2006
    Publication date: December 20, 2007
    Applicant: JASON LIFE TECH INC. LTD.
    Inventors: Tzyy-Rong Jinn, Yi-Ching Chen, Tze-Cheng Tzen, Balance Chih-Ming Chen
  • Publication number: 20070293462
    Abstract: The present invention discloses an inhibitive effect of Na+-K+-ATPase caused by a compound selected from the group consisting of magnesium lithospermate B (MLB), isomer, prodrug, derivative, pharmaceutically acceptable salt, and a composition thereof. In this invention, the variations of Na+-K+-ATPase activity were monitored with increasing MLB concentrations, and the result shows the Na+-K+ ATPase activity is repressed by MLB. An outcome of the inhibitory effect, the function of cellular sodium/potassium lo exchanger is reduced and cellular calcium ion concentration is increased. That is, the MLB is useful for inhibiting the function of cellular Na+-K+ pump, and further brings the utility for cardiac stimulation, diuretic enhancement, heart failure curing, and so on.
    Type: Application
    Filed: June 19, 2006
    Publication date: December 20, 2007
    Applicant: JASON LIFE TECH INC. LTD.
    Inventors: Tzyy-Rong Jinn, Yi-Ching Chen, Tze-Cheng Tzen
  • Patent number: 7262051
    Abstract: The present invention relates to use of bicistronic DNA constructs for identifying compounds that inhibits IRES-dependent translation activity of an infectious enterovirus (EV) or encephalomyocarditis virus (EMCV) without affecting CAP-dependent translation activity of a host subject. The compounds thus identified are useful in preparation of a medicament for treating EV or EMCV infection.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: August 28, 2007
    Assignee: Chung Yuan Christian University
    Inventors: Tzong-Yuan Wu, Tsu-An Hsu, Shin-Ru Shih, Suey-Sheng Kao, Tzyy-Rong Jinn, Shin-Jhan Zeng, Ying-Ju Chen
  • Patent number: 7261886
    Abstract: An insect larva aerosol infection method for producing recombinant proteins and baculovirus bio-insecticides is disclosed. A liquid spray of budded form baculoviruses are employed to infect insect larvae in order to reduce the manpower for manual injections and the energy wasted in feeding infection technologies. The invention may be applied to the production of recombinant proteins and baculoviruses as the production platform for bio-insecticides.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: August 28, 2007
    Assignee: Council of Agriculture, Executive Yuan
    Inventors: Tzong-Yuan Wu, Suey-Sheng Kao, Tzyy-Rong Jinn
  • Publication number: 20060024680
    Abstract: The present invention relates to use of bicistronic DNA constructs for identifying compounds that inhibits IRES-dependent translation activity of an infectious enterovirus (EV) or encephalomyocarditis virus (EMCV) without affecting CAP-dependent translation activity of a host subject. The compounds thus identified are useful in preparation of a medicament for treating EV or EMCV infection.
    Type: Application
    Filed: August 6, 2004
    Publication date: February 2, 2006
    Inventors: Tzong-Yuan Wu, Tsu-An Hsu, Shin-Ru Shih, Suey-Sheng Kao, Tzyy-Rong Jinn, Shin-Jhan Zeng, Ying-Ju Chen
  • Publication number: 20050125847
    Abstract: The present invention provides a method of tracking the presence of genetic modified baculoviruses (GMBVs) in pest insects, comprising infecting the pest insects with GMBVs, which are engineered to express tracer proteins, i.e., coral red fluorescence proteins. The color of the expressed coral red fluorescence proteins are red or pink and are bright enough to be seen by naked eyes under direct sunlight, thereby enabling the pest insects that are infected with GMBVs to be easily distinguished from the uninfected ones.
    Type: Application
    Filed: November 23, 2004
    Publication date: June 9, 2005
    Inventors: Tzong-Yuan Wu, Feng-Ming Yang, Suey-Sheng Kao, Tzyy-Rong Jinn
  • Publication number: 20050074432
    Abstract: This specification discloses an insect larva aerosol infection method for producing recombinant proteins and baculovirus bio-insecticides. Liquid spray of budding form baculoviruses are employed to infect insect larvae to reduce the manpower for manual injections and energy waste in feeding infection technologies. The invention can be applied to the production of recombinant proteins and baculoviruses as the production platform for bio-insecticides.
    Type: Application
    Filed: September 22, 2004
    Publication date: April 7, 2005
    Inventors: Tzong-Yuan Wu, Suey-Sheng Kao, Tzyy-Rong Jinn